These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

440 related articles for article (PubMed ID: 34645582)

  • 1. Genetic Profiling of Cell-Free DNA From Pleural Effusion in Advanced Lung Cancer as a Surrogate for Tumor Tissue and Revealed Additional Clinical Actionable Targets.
    Tu HY; Li YS; Bai XY; Sun YL; Zheng MY; Ke EE; Liao RQ; Jiang BY; Lin JX; Huang J; Xu BF; Yang JJ; Zhang XC; Zhou Q; Wang BC; Chen HJ; Tong X; Yu R; Wu X; Zhu D; Wu YL
    Clin Lung Cancer; 2022 Mar; 23(2):135-142. PubMed ID: 34645582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-derived DNA from pleural effusion supernatant as a promising alternative to tumor tissue in genomic profiling of advanced lung cancer.
    Tong L; Ding N; Tong X; Li J; Zhang Y; Wang X; Xu X; Ye M; Li C; Wu X; Bao H; Zhang X; Hong Q; Song Y; Shao YW; Bai C; Zhou J; Hu J
    Theranostics; 2019; 9(19):5532-5541. PubMed ID: 31534501
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct profile of cell-free DNA in malignant pleural effusion of non-small cell lung cancer and its impact on clinical genetic testing.
    Yu Y; Qian J; Shen L; Ji W; Lu S
    Int J Med Sci; 2021; 18(6):1510-1518. PubMed ID: 33628109
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pleural effusion supernatant: a reliable resource for cell-free DNA in molecular testing of lung cancer.
    Thakur S; Rathor A; Jain S; Nambirajan A; Khurana S; Malik PS; Jain D
    J Am Soc Cytopathol; 2024; 13(4):291-302. PubMed ID: 38704351
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of Non-Small-Cell Lung Cancer Based on Circulating Cell-Free DNA and Impact of Variation Allele Frequency.
    Bustamante Alvarez JG; Janse S; Owen DH; Kiourtsis S; Bertino EM; He K; Carbone DP; Otterson GA
    Clin Lung Cancer; 2021 Jul; 22(4):e519-e527. PubMed ID: 33414052
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characteristics of Genomic Alterations in Pericardial Effusion of Advanced Non-small Cell Lung Cancer.
    He J; Hu X; Chen L; Liu Q; Jiang Y
    Front Genet; 2022; 13():850290. PubMed ID: 35646096
    [No Abstract]   [Full Text] [Related]  

  • 7. Differences in the genomic profiles of cell-free DNA between plasma, sputum, urine, and tumor tissue in advanced NSCLC.
    Wu Z; Yang Z; Li CS; Zhao W; Liang ZX; Dai Y; Zhu Q; Miao KL; Cui DH; Chen LA
    Cancer Med; 2019 Mar; 8(3):910-919. PubMed ID: 30767431
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Testing for EGFR Variants in Pleural and Pericardial Effusion Cell-Free DNA in Patients With Non-Small Cell Lung Cancer.
    Lee KWC; Li MSC; Gai W; Lau YM; Chan AKC; Chan OSH; Lee CK; Yeung RMW; Fung SYH; Cheung WF; Chan VW; Leung L; Kam KNP; Mok TSK
    JAMA Oncol; 2023 Feb; 9(2):261-265. PubMed ID: 36580285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Outcomes for Plasma-Based Comprehensive Genomic Profiling Versus Standard-of-Care Tissue Testing in Advanced Non-Small Cell Lung Cancer.
    Page RD; Drusbosky LM; Dada H; Raymond VM; Daniel DB; Divers SG; Reckamp KL; Villalona-Calero MA; Dix D; Odegaard JI; Lanman RB; Papadimitrakopoulou VA; Leighl NB
    Clin Lung Cancer; 2022 Jan; 23(1):72-81. PubMed ID: 34782240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liquid biopsy using ascitic fluid and pleural effusion supernatants for genomic profiling in gastrointestinal and lung cancers.
    Wu H; Ji H; Yang W; Zhang M; Guo Y; Li B; Wang J; Chen R; Chen Y; Wang X
    BMC Cancer; 2022 Sep; 22(1):1020. PubMed ID: 36167530
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Large-Scale Prospective Concordance Study of Plasma- and Tissue-Based Next-Generation Targeted Sequencing for Advanced Non-Small Cell Lung Cancer (LC-SCRUM-Liquid).
    Sugimoto A; Matsumoto S; Udagawa H; Itotani R; Usui Y; Umemura S; Nishino K; Nakachi I; Kuyama S; Daga H; Hara S; Miyamoto S; Kato T; Sakakibara-Konishi J; Tabata E; Nakagawa T; Kawaguchi T; Sakai T; Shibata Y; Izumi H; Nosaki K; Zenke Y; Yoh K; Goto K
    Clin Cancer Res; 2023 Apr; 29(8):1506-1514. PubMed ID: 36201167
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Heterogeneous mutation pattern in tumor tissue and circulating tumor DNA warrants parallel NGS panel testing.
    Guo Q; Wang J; Xiao J; Wang L; Hu X; Yu W; Song G; Lou J; Chen J
    Mol Cancer; 2018 Aug; 17(1):131. PubMed ID: 30153823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multigene PCR using both cfDNA and cfRNA in the supernatant of pleural effusion achieves accurate and rapid detection of mutations and fusions of driver genes in patients with advanced NSCLC.
    Chen X; Li K; Liu Z; Gai F; Zhu G; Lu S; Che N
    Cancer Med; 2021 Apr; 10(7):2286-2292. PubMed ID: 33656807
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Biomarker Discovery and Outcomes for Comprehensive Cell-Free Circulating Tumor DNA Versus Standard-of-Care Tissue Testing in Advanced Non-Small-Cell Lung Cancer.
    Palmero R; Taus A; Viteri S; Majem M; Carcereny E; Garde-Noguera J; Felip E; Nadal E; Malfettone A; Sampayo M; Riva F; Nagy RJ; Lanman RB; Faull I; Dix D; Karachaliou N; Rosell R
    JCO Precis Oncol; 2021 Nov; 5():93-102. PubMed ID: 34994593
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy Program.
    Park S; Olsen S; Ku BM; Lee MS; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Choi YL; Ahn MJ
    Cancer; 2021 Aug; 127(16):3019-3028. PubMed ID: 33826761
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-free DNA From Pleural Effusion Samples: Is It Right for Molecular Testing in Lung Adenocarcinoma?
    Mokánszki A; Bádon ES; Mónus A; Tóth L; Bittner N; Méhes G
    Pathol Oncol Res; 2021; 27():613071. PubMed ID: 34257581
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Liquid biopsy-based tumor profiling for metastatic colorectal cancer patients with ultra-deep targeted sequencing.
    Kang JK; Heo S; Kim HP; Song SH; Yun H; Han SW; Kang GH; Bang D; Kim TY
    PLoS One; 2020; 15(5):e0232754. PubMed ID: 32379795
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy.
    Li YS; Jiang BY; Yang JJ; Zhang XC; Zhang Z; Ye JY; Zhong WZ; Tu HY; Chen HJ; Wang Z; Xu CR; Wang BC; Du HJ; Chuai S; Han-Zhang H; Su J; Zhou Q; Yang XN; Guo WB; Yan HH; Liu YH; Yan LX; Huang B; Zheng MM; Wu YL
    Ann Oncol; 2018 Apr; 29(4):945-952. PubMed ID: 29346604
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Malignant pleural effusion supernatant is an alternative liquid biopsy specimen for comprehensive mutational profiling.
    Guo Z; Xie Z; Shi H; Du W; Peng L; Han W; Duan F; Zhang X; Chen M; Duan J; Lin J; Chen X; Lizaso AA; Han-Zhang H; He J; Yin W
    Thorac Cancer; 2019 Apr; 10(4):823-831. PubMed ID: 30779318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted Molecular Profiling of Circulating Cell-Free DNA in Patients With Advanced Hepatocellular Carcinoma.
    Cowzer D; White JB; Chou JF; Chen PJ; Kim TH; Khalil DN; El Dika IH; Columna K; Yaqubie A; Light JS; Shia J; Yarmohammadi H; Erinjeri JP; Wei AC; Jarnagin W; Do RKG; Solit DB; Capanu M; Shah RH; Berger MF; Abou-Alfa GK; Harding JJ
    JCO Precis Oncol; 2023 Sep; 7():e2300272. PubMed ID: 37769223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.